Vertex Pharmaceuticals

Lonza and Vertex Sign a Commercial Supply Agreement for Casgevy

Lonza and Vertex Pharmaceuticals recently announced a commercial supply agreement for casgevy (exagamglogene autotemcel).

Vertex to Acquire Alpine Immune Sciences for $4.9 Billion

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

RoslinCT to Join Manufacturing Network for CRISPR-Based Therapy

UK’s RoslinCT, a cell and gene therapy contract development and manufacturing organization, will be part of the Vertex Pharmaceuticals global network producing the CRISPR-based therapy exa-cel, which will be used for treatment of sickle cell disease and transfusion-dependent beta thalassemia.

Lonza, Vertex Break Ground on New US Cell Therapy Plant

Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.

Vertex Buys ViaCyte for $320 Million

US-based Vertex Pharmaceuticals has agreed to pay $320 million in cash to acquire ViaCyte, a compatriot private cellular therapy company specializing in a treatment for type-1 diabetes (T1D). The transaction is expected to close later this year.

Continuous Pharmaceutical Manufacturing

Top-Selling Drugs for Ultra-Rare Diseases

Entering the Age of the $1 Million Medicine

US FDA New Drug Approvals Hit 16-Year High in 2012

Vertex Posts Q3 Loss as Hepatitis Drug Sales Plunge

Surge in Biotech Deals to Unlock Big Investor Profits

U.S. Medicine Spending Rose to $320 Billion Last Year